Please login to the form below

Not currently logged in
Email:
Password:

Castleman's disease

This page shows the latest Castleman's disease news and features for those working in and with pharma, biotech and healthcare.

World Castleman Disease Day

World Castleman Disease Day

Gary’s story. I was a very healthy, active guy for a long time and had been a carpenter for 27 years when Castleman Disease knocked me down in just a ... About Castleman disease. Castleman disease (CD) is the name given to a group of rare and

Latest news

  • Roche snags pair of FDA breakthrough designations Roche snags pair of FDA breakthrough designations

    drug. In J-ALEX - conducted by Roche's Japanese subsidiary Chugai - Alecensa reduced the risk of disease-worsening or death by 66% compared to Xalkori. ... First launched in Japan for 2005 for Castleman's disease - and subsequently getting the green

  • Roche wins early use RA approval for RoActemra in Europe Roche wins early use RA approval for RoActemra in Europe

    Adds to existing indications in arthritis and Castleman’s disease. Roche's arthritis brand RoActemra (tocilizumab) has widened its European licence, winning a new EU indication to treat early rheumatoid arthritis. ... The study showed patients on the

  • EC approves Janssen rare blood disorder drug EC approves Janssen rare blood disorder drug

    Sylvant available to treat multicentric Castleman's disease. Janssen's Sylvant this week became the first drug approved in Europe to treat the rare blood disorder multicentric Castleman's disease (MCD). ... rare and challenging disease and further

  • FDA approves Janssen drug for rare Castleman’s disease FDA approves Janssen drug for rare Castlemans disease

    Sylvant approved to treat lymphoma-like condition. The US FDA has approved a new drug to treat a rare cancer-like condition known as multicentric Castleman's disease. ... It is also designated an orphan drug due to the rarity of multicentric Castleman's

  • EMA backs Janssen rare disease drug for approval EMA backs Janssen rare disease drug for approval

    Castleman's disease treatment Sylvant wins CHMP recommendation. J&J subsidiary Janssen-Cilag's Castleman's disease treatment Sylvant (situximab) has been recommended for approval in Europe. ... Castleman's disease is a rare disorder characterised by

More from news
Approximately 3 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics